ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Feb 2026
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
March 2026
Nuclear Technology
February 2026
Fusion Science and Technology
January 2026
Latest News
Fusion energy: Progress, partnerships, and the path to deployment
Over the past decade, fusion energy has moved decisively from scientific aspiration toward a credible pathway to a new energy technology. Thanks to long-term federal support, we have significantly advanced our fundamental understanding of plasma physics—the behavior of the superheated gases at the heart of fusion devices. This knowledge will enable the creation and control of fusion fuel under conditions required for future power plants. Our progress is exemplified by breakthroughs at the National Ignition Facility and the Joint European Torus.
Greg Staack, Yung-Sung Cheng, Yue Zhou, Tom LaBone
Fusion Science and Technology | Volume 71 | Number 4 | May 2017 | Pages 570-574
Technical Note | doi.org/10.1080/15361055.2017.1291041
Articles are hosted by Taylor and Francis Online.
Samples of tritiated LaNi4.15Al0.85 (LANA.85) and 13X zeolite were analyzed to obtain particle size distributions and tritium evolution rates in a simulated lung environment. This information was used to calculate intake-to-dose conversion factors (DCFs), which estimate the committed effective dose (CED) a worker would receive after inhaling either tritiated particulate. The DCFs for tritiated LANA.85 and 13X particulate with a default activity mean aerodynamic diameter (AMAD) of 5 μm were determined to be 1.01E-11 Sv/Bq and 1.11E-11 Sv/Bq, respectively. These results are comparable to that of HTO, 1.8E-11 Sv/Bq, indicating that urine bioassay results can conservatively estimate the dose delivered if the worker was exposed to any mixture of HTO, LANA.85, or 13X.
